enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 171,700 shares, a growth of 7.1% from the June 30th total of 160,300 shares. Based on an average trading volume of 118,400 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.4% of the company’s shares are sold short.

Institutional Investors Weigh In On enGene

Several hedge funds have recently bought and sold shares of the business. BVF Inc. IL bought a new position in shares of enGene in the fourth quarter worth approximately $20,777,000. Omega Fund Management LLC bought a new position in shares of enGene in the fourth quarter worth approximately $10,441,000. Janus Henderson Group PLC bought a new position in shares of enGene in the first quarter worth approximately $17,095,000. Vivo Capital LLC bought a new position in shares of enGene in the fourth quarter worth approximately $6,264,000. Finally, Altitude Crest Partners Inc. bought a new position in shares of enGene in the first quarter worth approximately $2,039,000. Institutional investors own 64.16% of the company’s stock.

Analyst Upgrades and Downgrades

ENGN has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of enGene in a research report on Monday, April 15th. They set a “buy” rating and a $34.00 price target on the stock. Wells Fargo & Company initiated coverage on shares of enGene in a research report on Monday, April 22nd. They set an “overweight” rating and a $30.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $34.40.

enGene Trading Down 6.0 %

NASDAQ:ENGN traded down $0.57 during mid-day trading on Thursday, hitting $8.93. 582,621 shares of the company’s stock were exchanged, compared to its average volume of 84,527. enGene has a one year low of $6.69 and a one year high of $43.00. The business has a fifty day moving average price of $9.23 and a 200 day moving average price of $12.24.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Friday, June 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.14). As a group, analysts forecast that enGene will post -1.33 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.